ARMATA PHARMACEUTICALS, INC. Business Acquisition, Pro Forma Net Income (Loss)
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Business Acquisition, Pro Forma Net Income (Loss) of -$21.34 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2020-03-19
- ARMATA PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for fiscal 2019 was -$21.34M.
- ARMATA PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for fiscal 2018 was -$27.82M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2019-12-31 | -$21.34M 10-K · filed 2020-03-19 |
| 2018-12-31 | -$27.82M 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |